Analysis of potential pharmacodynamic mechanism of Yiqi-Sanyu-Jiedu Formula in treatment of osteosarcoma based on network pharmacology and molecular docking

Mengchen YIN; Hongshen WANG; Yijun SUN; Shengming XU; Chongqing XU; Yinjie YAN; Zhaoxiang FAN; Junming MA; Wen MO; Qi SHI

doi:10.16305/j.1007-1334.2021.2004099

您当前的位置：

首页 >

文章列表页 >

Analysis of potential pharmacodynamic mechanism of Yiqi-Sanyu-Jiedu Formula in treatment of osteosarcoma based on network pharmacology and molecular docking

更新时间：2022-08-03

- Analysis of potential pharmacodynamic mechanism of Yiqi-Sanyu-Jiedu Formula in treatment of osteosarcoma based on network pharmacology and molecular docking
- Shanghai Journal of Traditional Chinese Medicine Vol. 55, Issue 7, Pages: 17-24,28(2021)
- 作者机构：
  
  1.上海中医药大学附属龙华医院（上海　200032）
  2.广东省中医院（广东　广州　510120）
  3.上海交通大学附属第六人民医院（上海　200233）
  4.上海中医药大学附属曙光医院（上海　201203）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2021.2004099
  CLC：
扫描看全文
Mengchen YIN, Hongshen WANG, Yijun SUN, et al. Analysis of potential pharmacodynamic mechanism of Yiqi-Sanyu-Jiedu Formula in treatment of osteosarcoma based on network pharmacology and molecular docking. [J]. Shanghai Journal of Traditional Chinese Medicine 55(7):17-24,28(2021)
DOI：

Mengchen YIN, Hongshen WANG, Yijun SUN, et al. Analysis of potential pharmacodynamic mechanism of Yiqi-Sanyu-Jiedu Formula in treatment of osteosarcoma based on network pharmacology and molecular docking. [J]. Shanghai Journal of Traditional Chinese Medicine 55(7):17-24,28(2021) DOI： 10.16305/j.1007-1334.2021.2004099.

摘要

目的,2,探讨益气散瘀解毒方治疗骨肉瘤的活性成分及其潜在作用机制。,方法,2,通过TCMSP、TCMID数据库及文献检索查找黄芪、重楼、黄连3味中药的活性成分及作用靶点；利用Genecards、OMIM、TTD数据库获取骨肉瘤相关靶基因；对药物靶点和疾病靶点取交集，运用Cytoscape 3.7.2软件构建“药物-靶点-疾病网络”；通过String数据库获取益气散瘀解毒方治疗骨肉瘤相关蛋白相互作用网络（PPI），利用Network Analyzer工具进行拓扑学分析；利用DAVID数据库对核心靶点进行GO功能富集分析和KEGG通路富集分析；利用AutoDock Vina软件将化合物与骨肉瘤相关蛋白进行分子对接。,结果,2,筛选得到益气散瘀解毒方中的共49种活性成分，关键活性成分共23个，治疗骨肉瘤的潜在靶点93个；PPI网络分析得出益气散瘀解毒方治疗骨肉瘤的17个关键靶点蛋白，涉及Akt1、MAPK1、PTGS2和VEGFA等。GO功能富集分析得到GO条目1 720个（,P,<,0.05），其中生物过程（BP）条目1 583个，细胞组成（CC）条目30个，分子功能（MF）条目107个。KEGG通路富集筛选得到112条信号通路（,P,<,0.05），涉及PI3K-Akt信号通路、MAPK信号通路、HIF-1信号通路等。分子对接结果显示，山柰酚、黄连素和槲皮素与骨肉瘤的Akt1、MAPK1蛋白具有较强的亲和力。,结论,2,益气散瘀解毒方中的活性成分可能通过作用于Akt1、MAPK1等靶点，调节多条信号通路，进而起到治疗骨肉瘤的作用。

Abstract

Objective,2,To explore the active ingredients, targets, potential action mechanism of Yiqi-Sanyu-Jiedu Formula in the treatment of osteosarcoma with network pharmacology and molecular docking technology.,Methods,2,All the active ingredients and action targets of astragalus, paris polyphylla and coptis were searched by TCMSP, TCMID and published literatures. Target genes related to osteosarcoma were obtained by Genecards, OMIM and TTD databases. The drug target and disease target were intersected, and the drug-target-disease network was constructed by using Cytoscape 3.7.2. PPI network for the treatment of osteosarcoma with Yiqi-Sanyu-Jiedu Formula was obtained by using the String database, and the Network Analyzer was used for topology analysis. The GO function enrichment analysis were obtainea by and KEGG pathway enrichment andysis of the wre taryets. The compound was molecularly docked with proteins associated with osteosarcoma by using AutoDock Vina.,Results:,2,A total of 49 active ingredients and 23 key active ingredients were screened. 93 potential targets for the treatment of osteosarcoma were screened. PPI network was used to obtain 42 key target proteins of Yiqi-Sanyu-Jiedu Formula for the treatment of osteosarcoma. The key targets involved Akt1, MAPK1, PTGS2 and VEGFA. GO functional enrichment analysis resulted in 1720 GO items (,P,<,0.05), including 1583 BP items, 60 CC items, and 107 MF items. KEGG pathway enrichment analysis resulted in 112 signaling pathways (,P,<,0.05), involving PI3K-Akt signaling pathway, MAPK signaling pathway, and hypoxia-inducible factor-1 signaling pathway. Molecular docking results showed that kaenophenol, berberine and quercetin had strong affinity with Akt1 and MAPK1 proteins of osteosarcoma.,Conclusion,2,The active ingredients in Yiqi-Sanyu-Jiedu Formula can act on Akt1, MAPK1 and other targets, so as to regulate multiple signaling pathways and play an important role in the treatment of osteosarcoma.

关键词

益气散瘀解毒方骨肉瘤网络药理学分子对接

Keywords

Yiqi-Sanyu-Jiedu Formulaosteosarcomanetwork pharmacologymolecular docking

references

MIR O, HONORÉ C, ADAM J. PD-1 inhibition in bone sarcoma and soft-tissue sarcoma[J]. Lancet Oncol, 2017, 18(11): 1430-1431.

MORROW J J, BAYLES I, FUNNELL A P W, et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence[J]. Nat Med, 2018, 24(2): 176-185.

WHENLAN J S, DAVIS L E. Osteosarcoma, chondrosarcoma, and chordoma[J]. J Clin Oncol, 2018, 36(2): 188-193.

SAYLES L C, BREESE M R, KOEHNE A L, et al. Genome-informed targeted therapy for osteosarcoma[J]. Cancer Discov, 2019, 9(1): 46-63.

SAVAGE S A, MIRABELLO L. Bone cancer: Is the osteosarcoma genome targetable[J]. Nat Rev Endocrinol, 2017, 13(9): 506-508.

何立丽，顾恪波，孙桂芝，等. 芪珍胶囊对气虚血瘀型非小细胞肺癌患者NP方案化疗的影响[J]. 中华中医药杂志，2015, 30(10): 3780-3784.

康毅，高峻，杨牡丹，等. FOLFOX4化疗方案联合芪珍胶囊治疗晚期胃癌的疗效观察[J].首都食品与医药，2015, 22(24): 80-83.

姚运秀，贺桢翔，刘晓凤，等. 基于网络药理学和分子对接技术的抗病毒颗粒治疗新型冠状病毒肺炎（COVID-19）的潜在物质基础研究[J]. 中草药，2020, 51(6): 1386-1396.

刘施吟，胡渊龙，陈宪海. 神术散治疗新型冠状病毒肺炎的分子机制研究[J]. 中药材， 2020, 43(4): 1038-1043.

BAO W R, LI Z P, ZHANG Q W, et al. Astragalus polysaccharide RAP selectively attenuates paclitaxel-induced cytotoxicity toward RAW264.7 cells by reversing cell cycle arrest and apoptosis[J/OL]. Front Pharmacol，2019[2020-03-19]. https://pubmed.ncbi.nlm.nih.gov/30804792/https://pubmed.ncbi.nlm.nih.gov/30804792/.

WANG H J, LIU A N, ZHAO W X, et al. Metabolomics research reveals the mechanism of action of astragalus polysaccharide in rats with digestive system disorders[J/OL]. Molecules, 2018[2020-01-19]. https://pubmed.ncbi.nlm.nih.gov/30558291/https://pubmed.ncbi.nlm.nih.gov/30558291/.

LI W F, HU X Y, WANG S P, et al. Detection and evaluation of anti-cancer efficiency of astragalus polysaccharide via a tissue engineered tumor model[J/OL]. Macromol Biosci, 2018[2020-02-22]. https://pubmed.ncbi.nlm.nih.gov/30188006/https://pubmed.ncbi.nlm.nih.gov/30188006/.

LIU D D, SU J R, LIN J S, et al. Activation of AMPK-dependent SIRT-1 by astragalus polysaccharide protects against ochratoxin A-induced immune stress in vitro and in vivo[J]. Int J Biol Macromol, 2018, 120(Pt A): 683-692.

WU S J. Effect of dietary astragalus membranaceus polysaccharide on the growth performance and immunity of juvenile broilers[J]. Poult Sci, 2018, 97(10): 3489-3493.

CHANG J L, LI Y M, WANG X Y, et al. Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/beta-catenin pathway in vitro and in vivo[J/OL]. Sci Rep, 2017[2020-01-19]. https://pubmed.ncbi.nlm.nih.gov/28790389/https://pubmed.ncbi.nlm.nih.gov/28790389/.

CHANG J L, WANG H S, WANG X Y, et al. Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells[J]. J Ethnopharmacol, 2015(170): 117-127.

施剑明，殷嫦嫦，孙维君，等. 槲皮素联合顺铂对人骨肉瘤MG-63细胞增殖及凋亡的影响[J].中国药理学通报，2014, 30(10): 1361-1366.

洪振强，高弘建，赵诣，等. 基于NF-κB信号通路的薯蓣皂苷元抗骨肉瘤作用机制研究[J]. 中华中医药杂志，2018, 33(2): 748-752.

洪振强，高弘建，伏勇. 薯蓣皂苷元抗骨肉瘤机制及与Wnt/β-catenin信号通路的关系[J].福建中医药大学学报，2013, 23(3): 11-14.

Views

587

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Network pharmacology and molecular docking study on the mechanism of action of puerarin for Alzheimer's disease

Mechanism analysis of berberine in the treatment of nonalcoholic steatohepatitis based on network pharmacology and in vitro experimental verification

Study on the mechanism of Compound Tripterygium Wilfordii Painkiller Granules on rheumatoid arthritis based on network pharmacology and molecular docking

Network pharmacological study on mechanism of Tenghuang Jiangu Tablet in the treatment of knee osteoarthritis

Mechanism analysis of Astragali Radix in treatment of Hashimoto’s thyroiditis based on network pharmacology and Molecular Docking Method

Related Author

No data

Related Institution

School of Integrative Medicine， Shanghai University of Traditional Chinese Medicine

School of Rehabilitation， Shanghai University of Traditional Chinese Medicine

Shanghai University of Traditional Chinese Medicine

Tongren Hospital， Shanghai Jiao Tong University School of Medicine

Department of Rheumatology， Shanghai Guanghua Hospital， Shanghai University of Traditional Chinese Medicine

⁰